102631-03-8

Basic information

• Product Name: N-(2,3-DiMethylphenyl)-3-nitrobenzaMide, 97%
• Synonyms: N-(2,3-DiMethylphenyl)-3-nitrobenzaMide, 97%;BAS 00369012;Oprea1_322494;Oprea1_547752;ST5299628;ZINC00329781
• CAS NO: 102631-03-8
• Molecular Formula: C₁₅H₁₄N₂O₃
• Molecular Weight: 270.28326
• Mol File: 102631-03-8.mol

Chemical Properties

• Melting Point: 171-172 °C(Solv: benzene (71-43-2))
• Boiling Point: 352.5±42.0 °C(Predicted)
• Appearance: /
• Density: 1.270±0.06 g/cm3(Predicted)
• PKA: 12.53±0.70(Predicted)
• CAS DataBase Reference: N-(2,3-DiMethylphenyl)-3-nitrobenzaMide, 97%(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,3-DiMethylphenyl)-3-nitrobenzaMide, 97%(102631-03-8)
• EPA Substance Registry System: N-(2,3-DiMethylphenyl)-3-nitrobenzaMide, 97%(102631-03-8)

Safety Data

• Hazardous Substances Data: 102631-03-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
N-(2,3-DiMethylphenyl)-3-nitrobenzaMide, 97% is used as a building block for the synthesis of various organic compounds. Its unique structure and functional groups make it a valuable intermediate in the preparation of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, N-(2,3-DiMethylphenyl)-3-nitrobenzaMide, 97% serves as a key intermediate in the development of new drugs. Its versatile chemical properties allow for the synthesis of a wide range of bioactive molecules with potential therapeutic applications.
Used in Chemical Reactions:
As a reagent, N-(2,3-DiMethylphenyl)-3-nitrobenzaMide, 97% is employed in various chemical reactions, such as coupling, condensation, and substitution reactions. Its high purity ensures that the reactions proceed with minimal interference from impurities, leading to higher yields and better product quality.
Used in Research and Development:
In academic and industrial research settings, N-(2,3-DiMethylphenyl)-3-nitrobenzaMide, 97% is utilized for the exploration of new chemical reactions, synthesis methods, and the development of novel compounds with specific properties. Its availability in high purity facilitates the study of reaction mechanisms and the optimization of synthetic routes.
Used in Quality Control and Analysis:
The high purity of N-(2,3-DiMethylphenyl)-3-nitrobenzaMide, 97% makes it an ideal reference material for quality control and analytical purposes. It can be used to calibrate instruments, validate analytical methods, and ensure the accuracy of measurements in various applications.

Upstream product

• 87-59-2 2,3-Dimethylaniline 
• 121-90-4 m-nitrobenzoic acid chloride 
• 121-92-6 3-nitrobenzoic acid 

Downstream Products

• 102630-86-4 3-amino-N-(2,3-dimethylphenyl)benzamide 

Relevant articles and documents

Design, synthesis and early structure-activity relationship of farnesyltransferase inhibitors which mimic both the peptidic and the prenylic substrate

Inhibition of the farnesylation of ras proteins has been identified as a promising target in tumor therapy. Only a few farnesyltransferase inhibitors are bisubstrate analogues displaying features of both substrates, the farnesylpyrophosphate and the C-terminal CAAX-tetrapeptide sequence of the ras protein. These known bisubstrate analogues consist of an AAX-tripeptide and a farnesyl residue connected through various linkers. We have developed a class of novel compounds that mimic a bisubstrate inhibitor structure and that differ from the known ones by lacking peptidic or farnesylic substructures. Long chain fatty acids and aryl-substituted carboxylic acids were used as farnesyl surrogates. These structures were linked to isoleucine amide, benzoic acid amide, N-substituted aminobenzenesulfonamides and N(α)-aryl-substituted methionine derivatives, respectively, which function as AA- or AAX-mimetics. Copyright (C) 2000 Elsevier Science Ltd.

Design, synthesis, and evaluation of novel modular bisubstrate analogue inhibitors of farnesyltransferase

Promising potential chemotherapeutics for the treatment of cancer can be developed from farnesyltransferase inhibitors. A novel class of modular bisubstrate farnesyltransferase inhibitors is presented that can be synthesized in a straightforward manner. A

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention comprises peptidomimetic compounds which comprise a suitably aniline and aminoalkylbenzene moieties. The instant compounds inhibit the farnesyl-protein transferase enzyme and the farnesylation of certain proteins. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.